---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-048252"
form_type: "8-K"
ticker: "ELAB"
cik: "0001840563"
company_name: "PMGC Holdings Inc."
filed_at: "2026-04-28T23:59:59+00:00"
generated_at: "2026-05-15T03:08:14.258324+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# PMGC subsidiary NorthStrive files U.S. patent for EL-22 muscle preservation in humans

## Summary
- New U.S. patent application (No. 19/655,160) covers EL-22 as a formulated pharmaceutical product for muscle loss.
- EL-22 uses myostatin-engineered probiotic technology targeting sarcopenia, disuse atrophy, and neurological disorders.
- The patent includes dosing regimens and formulations; potential use with GLP-1 receptor agonist weight loss treatments.
- This filing expands NorthStrive's IP strategy for muscle health therapeutics across pharmaceutical and adjacent markets.

## SEC filing metadata
- accession: 0001213900-26-048252
- form_type: 8-K
- ticker: ELAB
- cik: 0001840563
- company_name: PMGC Holdings Inc.
- filed_at: 2026-04-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840563/000121390026048252/0001213900-26-048252-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840563/000121390026048252/ea0287845-8k_pmgc.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-048252
- JSON: https://secwatch.observer/filing/0001213900-26-048252.json
- Plain text: https://secwatch.observer/filing/0001213900-26-048252.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.